CHANGCHUN, China and LOS ANGELES, Dec. 10 /PRNewswire-Asia-FirstCall/ -- China Yongxin Pharmaceuticals, Inc. (OTC Bulletin Board: CYXN) ("Yongxin" or "the Company"), a leading pharmaceutical distributor and chain drugstore operator, today announced financial results for the third quarter ended September 30, 2009.
"While we recognize that many of our products depend on discretionary spending, we expect as the economy continues to recover and consumer confidence picks up further, sales will gain momentum in 2010 and beyond. In the third quarter, we maintained our sales activities and saw improved gross margin as the Company's shift to higher margin products in its retail segment contributed to a more profitable mix of business. Management believes that overall gross profit will continue to improve for the remainder of 2009 and into next year," commented Mr. Yongxin Liu, Chairman and Chief Executive Officer of Yongxin.
"Further, we have initiated distribution of essential drugs and believe the government's new efforts on centralized distribution and the broader healthcare reform provide a myriad of growth opportunities. As one of the leading drug distributors in Northeastern China, we are well positioned to capitalize on these developments and build sustainable and long-term shareholder value," concluded Mr. Liu.
Highlights for the three months Ended September 30, 2009
Net revenue totaled approximately $10.8 million for the three months ended September 30, 2009, a decline of 29.8% from $15.5 million for the same period of 2008, due to lower sales from the Company's wholesale business as result of a change in its sales strategy. In the third quarter, Yongxin shifted its focus to the retail sector as the benefits from China's proposed National Medical Policy for the Company's wholesale business segment have taken longer than initially anticipated.
Cost of goods sold for the third quarter of 2009 decreased to $12.4 million, or 70.9% of net revenue, from $7.7 million, or 80.3% in the 2008 third quarter, largely in line with sales decline.
Gross profit for the three months ended September 30, 2009 totaled $3.1 million, or 29.1% of net sales, compared with gross profit of $3.0 million, or 19.7% of net sales, for the same period of 2008. The improvement in gross margin was mainly due to a better sales mix and a focus on higher margin products, including cosmetics and certain health and organic products.
Operating expenses totaled approximately $3.3 million for the third quarter of 2009, up 168.7% from $1.2 million in the third quarter of 2008. As a percentage of net revenue, third-quarter 2009 total operating expenses amounted to 30.4%, compared to third-quarter 2008 operating expenses at 7.9% of net revenue. This was largely attributable to a sharp increase in general and administrative expenses, which more than quintupled in the third quarter, primarily driven by allowance for doubtful accounts for accounts receivable and accrued litigation fees. Selling expenses rose moderately by 6.3% as the Company opened two new retail stores during the third quarter.
Other income amounted to $1.1 million for the three months ended September 30, 2009, an increase of 85.5% from $0.5 million for the same period in 2008, largely due to higher sponsorship and rebates from customers and suppliers in combination with an 87.6% decline in interest expenses.
The Company's net income attributable to common shares during the three months ended September 30, 2009 was $0.5 million down 71.5% from $1.7 million for the three months ended September 30, 2008. In addition to higher operating expenses, third-quarter net income was also negatively affected by a change in the collection of sponsorship fees and rebates from customers and suppliers from an annual basis to a quarterly basis.
The earnings per basic and diluted share were $0.01 for the three months ended September 30, 2009, down from $0.05 for the three months ended September 30, 2008.
Nine Months Results Ended September 30, 2009
Total revenue for the first nine months of 2009 was approximately $29.2 million, down 35.1% from the first nine months of 2008. Gross profit for the first nine months of 2009 was $8.0 million, a decrease of 3.7% from gross profit of $8.4 million in the comparable period a year ago. Gross margin was 27.8% for the first nine months of 2009, up from 18.7% for the same period in 2008. The Company recorded an operating income of $1.7 million, compared with operating income of $4.4 million in the first nine months of 2008. Net income attributable to common shares for the first nine months of 2009 was $1.9 million, compared with $3.1 million in the first nine months of 2008. Basic and diluted earnings per share were $0.06 for the first nine months of 2009 compared to 0.10 in the first nine months of 2008.
As of September 30, 2009, Yongxin had 1.4 million in cash and cash equivalents, and approximately $12.1 million in working capital. As of September 30, 2009, shareholders' equity was $20.5 million. For the first nine months of 2009, the Company generated $2.6 million in cash from operations versus $3.7 million for the same period in 2008.
Yongxin announced on November 30 that it has completed preparation for distribution of medicines on the Essential Drug List, which was recently formalized by the Chinese government. Drugs on the National Essential Drugs List will be purchased and distributed to medical facilities including hospitals, clinics, pharmacies, etc. All drugs on the List will be covered by the basic insurance plan supported by the government. The government will invite public bidding for centralized distribution for essential drugs. Currently, Yongxin distributes 297 products out of 307 drugs listed on EDL. As one of the top medicine distributors in Jilin province with modern pharmaceutical logistic center, China Yongxin launched corresponding business preparation for public bidding and distribution for the first batch of 138 township hospitals and 11 city hospitals in Jilin province. The official public bidding is expected to be announced before the end of 2009. The winning of first batch will increase revenues of drug distribution and will help facilitate winning other batches of hospitals.
About China Yongxin Pharmaceuticals, Inc.
China Yongxin Pharmaceuticals, Inc. was founded in 1993 as the Changchun Yongxin Dirui Medical Co., Ltd. (Yongxin), a wholesale drug distributor. Its products include Chinese traditional medicines, pharmaceutical preparations, natural health products, health food, cosmetics, and medical equipment. It began retail operations in 2004, and in 2005, it gained franchise rights from one of the world's largest drug chains for China's Jilin Province. By the end of 2007, the Company had become one of the fastest growing pharmaceutical companies in China through its retail chain of 93 drug outlets as well as wholesale distribution and manufacturing operations in Northeastern China. For more information about China Yongxin Pharmaceuticals, please visit http://www.yongxinchina.com .
This news release contains certain "forward-looking statements." Forward- looking statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and many of which are beyond the Company's control. The forward-looking statements are also identified through the use of words "believe," enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict" "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from these forward-looking statements as a result of a number of risk factors detailed in the Company's periodic reports filed with the SEC. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and no assurances can be given that such statements will be achieved. China Yongxin Pharmaceutical Inc. does not assume any duty to publicly update or revise the material contained herein.
CHINA YONGXIN PHARMACEUTICALS INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS AS OF SEPTEMBER 30, 2009 AND DECEMBER 31, 2008 (UNAUDITED) September 30, December 31, 2009 2008 ASSETS Current Assets: Cash and cash equivalents $1,371,842 $609,422 Accounts receivable, net 6,622,395 6,030,874 Notes receivable 3,074,753 1,334,078 Other receivable, net 2,823,356 356,573 Advances to suppliers 6,576,641 6,186,269 Prepaid expenses -- 345,686 Inventory, net 8,747,431 7,864,677 Total Current Assets 29,216,418 22,727,579 Property and Equipment, net 8,733,094 2,680,207 Construction In Progress 913,054 6,066,249 Intangible Assets, net 47,324 73,687 Total Assets $38,909,890 $31,547,722 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable $4,923,000 $3,255,148 Accrued expenses & other payable 4,496,232 2,412,067 Advances from customers 2,901,552 2,580,894 Tax payable 2,183,714 1,240,411 Loans to related parties 184,662 184,662 Short-term loans payable 1,439,578 1,967,185 Deferred income 305,340 273,753 Shares to be issued 47,000 35,000 Net liabilities of discontinued operations 628,837 628,837 Total Current Liabilities 17,109,915 12,577,957 Long term loan 1,320,300 1,320,390 Commitments and Contingency -- -- Stockholders' Equity: Preferred stock, $0.001 par value; 5,000,000 shares authorized; 5,000,000 shares issued and outstanding 5,000 5,000 Common stock; $0.001 par value; 75,000,000 shares authorized; 32,110,540 shares issued and outstanding as of September 30, 2009 and 31,400,540 shares issued and outstanding as of December 31, 2008 32,111 31,401 Additional paid in capital 719,536 615,906 Deferred consulting expense - issuance of warrants (11,850) (72,815) Prepaid consulting - issuance of shares (12,500) (68,750) Receivable from a related party (50,000) (50,000) Statutory reserve 2,170,805 1,841,241 Other comprehensive income 1,685,247 1,684,649 Retained earnings 11,171,145 9,563,803 Non-controlling interest 4,770,180 4,098,940 Total Stockholders' Equity 20,479,675 17,649,375 Total Liabilities and Stockholders' Equity $38,909,890 $31,547,722 CHINA YONGXIN PHARMACEUTICALS INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF INCOME FOR THE THREE-MONTH AND NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2009 AND 2008 (UNAUDITED) For the Three-Month For the Nine-Month Periods Ended Periods Ended September 30, September 30, 2009 2008 2009 2008 Net Revenues $10,844,786 $15,451,100 $29,199,325 $45,025,197 Cost of Goods Sold (7,685,369) (12,412,576) (21,090,595) (36,602,807) Gross profit 3,159,417 3,038,524 8,108,730 8,422,390 Operating Expenses: Selling expenses 912,094 858,038 2,495,546 2,582,411 General and administrative expenses 2,386,349 369,471 3,908,223 1,482,786 Total operating Expenses 3,298,443 1,227,509 6,403,769 4,065,197 Income (Loss) From Operations (139,026) 1,811,015 1,704,961 4,357,193 Other Income (Expense): Other income 1,112,309 683,618 1,906,864 1,517,758 Other expense (19,981) (42,745) (40,763) (77,651) Interest income (expense) (6,919) (55,845) 1,066 (282,957) Total other income 1,085,409 585,028 1,867,166 1,157,150 Operating Income Before Income Tax and Non controlling Interest 946,383 2,396,043 3,572,127 5,514,343 Provision for income tax (233,908) (547,088) (964,474) (1,487,230) Net Income Before Non controlling Interest 712,475 1,848,955 2,607,653 4,027,113 Non controlling interest (240,362) (191,894) (670,747) (883,775) Net Income 472,113 1,657,061 1,936,906 3,143,338 Other Comprehensive Item: Foreign exchange translation gain 18,938 26,258 598 862,970 Net Comprehensive Income 491,051 1,683,319 1,937,504 $4,006,308 Earning per share Basic $0.01 $0.05 $0.06 $0.10 Diluted $0.01 $0.05 $0.06 $0.10 Weighted average number of shares outstanding Basic 31,667,062 31,291,845 31,288,904 31,150,819 Diluted 32,125,923 31,291,845 31,747,765 31,150,819
SOURCE China Yongxin Pharmaceuticals, Inc.
|SOURCE China Yongxin Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved